FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W215989810> ?p ?o ?g. }

• W215989810 abstract "Abstract In acute lymphoblastic leukemia (ALL), central nervous system (CNS) prophylaxis with cranial irradiation plus 5 doses of intrathecal methotrexate (i.t. MTX) reduces the incidence of CNS relapse to 7%-15%. However, increased evidence of CNS delayed toxicity started to be recognized as CT scan abnormalities and neuropsychologic alterations, mainly in children. Two questions were analyzed in the present report: (1) Will further doses of i.t. methotrexate and dexamethasone (i.t. MTX- DMT) decrease the incidence of CNS relapse in patients treated early in remission with cranium irradiation plus i.t. MTX-DMT even more? (2) Is i.t. MTX-DMT given during induction and maintenance equally as effective as cranium irradiation plus i.t. MTX-DMT? A randomized study was designed to answer the first question. Incidence of primary CNS relapse in i.t. MTX-DMT-treated patients with a WBC count less than 50,000 was 11% (15 of 135 patients) and was 11% (17 of 150) in the untreated group. In patients with a WBC count greater than 50,000, it was 16% (6/37) in the treated group and 19% (6/31) in the control group. No difference was observed according to treatment in both prognostic groups. Patients in this study were retrospectively compared with a consecutive protocol in which patients received 3 doses of i.t. MTX-DMT alone during induction plus 3 doses weekly during the first month of remission and every 3 mo thereafter. The incidence of primary CNS leukemia at 60 mo in patients with a WBC count less than 50,000 was 20% in the irradiated group and 32% in the group with i.t. MTX-DMT alone. This difference was not significant. However, the relapse-free survival at 60 mo was 26% and 41%, respectively, (p less than 0.0005). The incidence of primary CNS relapse in patients with a WBC count more than 50,000 at 48 mo was 28% in the irradiated group and 42% in the nonirradiated group. The difference was not significant. The duration of complete remission was similar, remaining at 15% and 16% of patients disease-free at 48 mo, respectively. We conclude that (A) after cranial irradiation plus i.t. MTX-DMT X 5, the use of additional doses of i.t. MTX-DMT is not of further benefit in preventing CNS relapse; (B) the use of i.t. MTX-DMT alone compares similarly with cranial irradiation plus i.t. MTX-DMT in the incidence of CNS relapse; and (C) relapse-free survival and survival in patients with a WBC count less than 50,000 were significantly longer in those without cranial irradiation." @default.
• W215989810 created "2016-06-24" @default.
• W215989810 creator A5023564722 @default.
• W215989810 creator A5034695712 @default.
• W215989810 creator A5034734954 @default.
• W215989810 creator A5038602216 @default.
• W215989810 creator A5040300777 @default.
• W215989810 creator A5050998314 @default.
• W215989810 creator A5055011540 @default.
• W215989810 creator A5062725846 @default.
• W215989810 creator A5083190653 @default.
• W215989810 creator A5086980912 @default.
• W215989810 creator A5088199010 @default.
• W215989810 creator A5089828940 @default.
• W215989810 date "1983-08-01" @default.
• W215989810 modified "2023-09-26" @default.
• W215989810 title "Comparison of central nervous system prophylaxis with cranial radiation and intrathecal methotrexate versus intrathecal methotrexate alone in acute lymphoblastic leukemia" @default.
• W215989810 cites W114182362 @default.
• W215989810 cites W1541118804 @default.
• W215989810 cites W1545516847 @default.
• W215989810 cites W1551433787 @default.
• W215989810 cites W1563811194 @default.
• W215989810 cites W1969861756 @default.
• W215989810 cites W1986655011 @default.
• W215989810 cites W1997522409 @default.
• W215989810 cites W1998323651 @default.
• W215989810 cites W2000417340 @default.
• W215989810 cites W2035001585 @default.
• W215989810 cites W2038252730 @default.
• W215989810 cites W2045402946 @default.
• W215989810 cites W2106147539 @default.
• W215989810 cites W2158049578 @default.
• W215989810 cites W2169953054 @default.
• W215989810 cites W2235132496 @default.
• W215989810 cites W2285218518 @default.
• W215989810 cites W2335900111 @default.
• W215989810 cites W2336821938 @default.
• W215989810 cites W2416276685 @default.
• W215989810 cites W338137436 @default.
• W215989810 cites W2411554573 @default.
• W215989810 doi "https://doi.org/10.1182/blood.v62.2.241.241" @default.
• W215989810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6575836" @default.
• W215989810 hasPublicationYear "1983" @default.
• W215989810 type Work @default.
• W215989810 sameAs 215989810 @default.
• W215989810 citedByCount "31" @default.
• W215989810 countsByYear W2159898102012 @default.
• W215989810 countsByYear W2159898102013 @default.
• W215989810 countsByYear W2159898102017 @default.
• W215989810 countsByYear W2159898102021 @default.
• W215989810 crossrefType "journal-article" @default.
• W215989810 hasAuthorship W215989810A5023564722 @default.
• W215989810 hasAuthorship W215989810A5034695712 @default.
• W215989810 hasAuthorship W215989810A5034734954 @default.
• W215989810 hasAuthorship W215989810A5038602216 @default.
• W215989810 hasAuthorship W215989810A5040300777 @default.
• W215989810 hasAuthorship W215989810A5050998314 @default.
• W215989810 hasAuthorship W215989810A5055011540 @default.
• W215989810 hasAuthorship W215989810A5062725846 @default.
• W215989810 hasAuthorship W215989810A5083190653 @default.
• W215989810 hasAuthorship W215989810A5086980912 @default.
• W215989810 hasAuthorship W215989810A5088199010 @default.
• W215989810 hasAuthorship W215989810A5089828940 @default.
• W215989810 hasBestOaLocation W2159898101 @default.
• W215989810 hasConcept C120665830 @default.
• W215989810 hasConcept C121332964 @default.
• W215989810 hasConcept C126322002 @default.
• W215989810 hasConcept C141071460 @default.
• W215989810 hasConcept C2778397455 @default.
• W215989810 hasConcept C2778461978 @default.
• W215989810 hasConcept C2780401358 @default.
• W215989810 hasConcept C2781059491 @default.
• W215989810 hasConcept C2781107101 @default.
• W215989810 hasConcept C2781382166 @default.
• W215989810 hasConcept C2909962599 @default.
• W215989810 hasConcept C529278444 @default.
• W215989810 hasConcept C61511704 @default.
• W215989810 hasConcept C71924100 @default.
• W215989810 hasConcept C90924648 @default.
• W215989810 hasConceptScore W215989810C120665830 @default.
• W215989810 hasConceptScore W215989810C121332964 @default.
• W215989810 hasConceptScore W215989810C126322002 @default.
• W215989810 hasConceptScore W215989810C141071460 @default.
• W215989810 hasConceptScore W215989810C2778397455 @default.
• W215989810 hasConceptScore W215989810C2778461978 @default.
• W215989810 hasConceptScore W215989810C2780401358 @default.
• W215989810 hasConceptScore W215989810C2781059491 @default.
• W215989810 hasConceptScore W215989810C2781107101 @default.
• W215989810 hasConceptScore W215989810C2781382166 @default.
• W215989810 hasConceptScore W215989810C2909962599 @default.
• W215989810 hasConceptScore W215989810C529278444 @default.
• W215989810 hasConceptScore W215989810C61511704 @default.
• W215989810 hasConceptScore W215989810C71924100 @default.
• W215989810 hasConceptScore W215989810C90924648 @default.
• W215989810 hasLocation W2159898101 @default.
• W215989810 hasOpenAccess W215989810 @default.
• W215989810 hasPrimaryLocation W2159898101 @default.
• W215989810 hasRelatedWork W1535543000 @default.
• W215989810 hasRelatedWork W2009872663 @default.
• W215989810 hasRelatedWork W2034655348 @default.

• next